Finance

Beta
Lists
038290:KOSDAQ
Macrogen Inc
â‚©12,180.00
-0.98%
(-120.00) 1D
Jul 2, 3:30:20 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 038290...
Open
â‚©12,250
High
â‚©12,310
Low
â‚©11,800
Mkt. cap
132.05B
Avg. vol.
45.15K
Volume
30.39K
Dividend
4.11%
Quarterly dividend
â‚©125
Ex-dividend date
Dec 27, 2024
P/E ratio
34.28
52-wk high
â‚©20,900
52-wk low
â‚©11,000
EPS
â‚©355
Shares outstanding
10.84M
No. of employees
475
Open
â‚©12,250
High
â‚©12,310
Low
â‚©11,800
Mkt. cap
132.05B
Avg. vol.
45.15K
Volume
30.39K
Dividend
4.11%
Quarterly dividend
â‚©125
Ex-dividend date
Dec 27, 2024
P/E ratio
34.28
52-wk high
â‚©20,900
52-wk low
â‚©11,000
EPS
â‚©355
Shares outstanding
10.84M
No. of employees
475
News stories
From sources across the web
Profile
Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia
About Macrogen Inc
CEOSeo Jeong-seon
Employees475
FoundedJun 5, 1997
Headquarters-
SectorHealth care
Websitemacrogen.com
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
48.99B
49.06B
56.26B
45.29B
Cost of goods sold
32.32B
30.68B
35.05B
28.68B
Cost of revenue
32.32B
30.68B
35.05B
28.68B
Research and development expenses
-
-
4.12B
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
17.35B
17.10B
6.79B
16.97B
Operating expense
18.19B
17.27B
17.57B
17.12B
Total operating expenses
50.51B
47.95B
52.62B
45.80B
Operating income
-1.53B
1.11B
3.64B
-508.86M
Other non operating income
-696.27M
985.86M
2.18B
-239.63M
EBT including unusual items
-2.32B
2.04B
3.49B
-796.15M
EBT excluding unusual items
-2.32B
2.04B
2.30B
-748.48M
Income tax expense
-55.36M
-46.70M
339.81M
30.55M
Effective tax rate
2.39%
-2.28%
9.75%
-3.84%
Other operating expenses
-
-
1.37B
-
Net income
-1.59B
2.46B
3.38B
-437.22M
Net profit margin
-3.24%
5.01%
6.00%
-0.97%
Earnings per share
-
-
-
-
Interest and investment income
-
-
748.82M
-
Interest expense
-
-
-2.52B
-
Net interest expenses
-
-
-1.77B
-
Depreciation and amortization charges
-
-
3.66B
-
EBITDA
1.17B
3.81B
7.98B
3.83B
Gain or loss from assets sale
-
-
88.53M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer